Performance characteristics between TDx®FLx and TBA™-25FR for the therapeutic drug monitoring of methotrexate

7Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Background: High-dose methotrexate (HDMTX) is used in the treatment of certain malignancies, including leptomeningeal metastases, systemic non-Hodgkin lymphoma, acute lymphoblastic leukemia, and osteosarcoma. High circulating levels of methotrexate can cause severe myelosuppression. The present study aimed to examine the differences in plasma MTX concentrations measured by two immunoassay systems currently available in the Japanese market, a TDX/FLX analyzer and a TBA-25FR analyzer. Methods: A total of 69 plasma samples from 16 patients were assayed by a fluorescence polarization immunoassay technique using a TDx/FLx analyzer (Abbott Diagnostics, Chicago, Illinois, U.S.A.) and a homogeneous enzyme immunoassay technique using a TBA-25FR analyzer (Toshiba Medical Systems, Tokyo, Japan). Results: Assay results were very consistent between the two systems, with good correlation 24 h after the start of treatment (TBA-25FR = 1.06·TDX/FLX, -1.31, r = 0.99), 48 h after the start of treatment (TBA-25FR = 1.00·TDX/FLX, +0.027, r > 0.99), and 72 h after the start of treatment (TBA-25FR = 1.09·TDX/FLX, +0.011, r > 0.99). Conclusions: The calibration curve spanned one order of magnitude with a linear working range from the lowest to the highest standard. The standard deviations show the excellent reproducibility of repeated measurements at each standard level for both immunoassay systems. However, when using the TBA-25FR, it is necessary to perform measurements in the low-concentration range with care.

References Powered by Scopus

Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity

361Citations
N/AReaders
Get full text

Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic Leukemia

348Citations
N/AReaders
Get full text

Patient characteristics associated with high-risk methotrexate concentrations and toxicity

199Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Progress in the chemotherapeutic treatment of osteosarcoma

196Citations
N/AReaders
Get full text

Discovery of a Highly Specific Anti-methotrexate (MTX) DNA Aptamer for Antibody-Independent MTX Detection

11Citations
N/AReaders
Get full text

Comparison of four immunoassays to an HPLC method for the therapeutic drug monitoring of methotrexate: Influence of the hydroxylated metabolite levels and impact on clinical threshold

11Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kaneko, T., Fujioka, T., Suzuki, Y., Sato, Y., & Itoh, H. (2016). Performance characteristics between TDx®FLx and TBATM-25FR for the therapeutic drug monitoring of methotrexate. Journal of Pharmaceutical Health Care and Sciences, 2(1). https://doi.org/10.1186/s40780-016-0042-y

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

50%

Researcher 3

50%

Readers' Discipline

Tooltip

Chemistry 2

29%

Medicine and Dentistry 2

29%

Biochemistry, Genetics and Molecular Bi... 2

29%

Pharmacology, Toxicology and Pharmaceut... 1

14%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 61

Save time finding and organizing research with Mendeley

Sign up for free